ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Bears Pile Into GME Again as BRVE Hits 277% Short

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

GME is back in the spotlight. Short interest jumped from 0.9% to 7.2% of free float in just seven days. That is a near 7x increase. Bears are rebuilding positions after years of meme-driven squeezes.

Braveheart Bio sits at the extreme end. Short interest hit 277% of free float. It rose 86 points in a week. That is the biggest absolute move in the market right now. No shares appear available to borrow, yet shorts keep finding ways in.

Wolfspeed remains a favourite bear target. SI stands at 81% of free float with 9.7 days to cover. Shorts trimmed slightly this week, down 3 points. The chip maker has lost 48% over three months. Cost to borrow stays low at 2.8%, leaving the trade cheap.

Hertz holds 69% SI. Zero shares are available to borrow. That raises squeeze risk.

On the covering side, Chewy saw shorts pull back 4.8 points to 73% of FF. Bears remain committed but the retreat is notable. Wolfspeed and Wix also saw modest covering.

Applied Aerospace & Defense drew fresh short attention. SI doubled from 6.4% to 15.9% this week. Space plays are polarising traders right now, with Space Exploration Technologies also seeing SI climb to 29.4%.

Lucky Strike Entertainment carries an ORTEX short score of 95 — near the top of the entire market. DTC stands at 26 days with CTB at 27%.

Stocks in this article

How this article was generated

Generated
22 Sept 2026, 12:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilization

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.